Revance Therapeutics Inc.
05/03/2024 | Press release | Distributed by Public on 05/03/2024 14:03
Submission of Matters to a Vote of Security Holders - Form 8-K
ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
At the Company's 2024 annual meeting of stockholders held on May 1, 2024, the stockholders voted on the three proposals listed below. The proposals are described in detail in the Company's definitive proxy statement for the 2024 annual meeting filed with the Securities and Exchange Commission on March 21, 2024 (the "2024 Proxy Statement"). The results of the matters voted upon at the meeting were:
1. Each of the Class I nominees of the Company's Board of Directors (the "Board") were elected to hold office until the Company's 2027 annual meeting of stockholders, as follows: Angus Russell: 46,115,633 shares of common stock voted for and 23,876,260 shares of common stock withheld; Julian Gangolli: 64,257,114 shares of common stock voted for and 5,734,779 shares of common stock withheld; and Olivia Ware: 52,294,395 shares of common stock voted for and 17,697,498 shares of common stock withheld. There were a total of 19,398,055 broker non-votes for the election of the Class I nominees. The terms of office of the Class II directors, Mark J. Foley and Christian W. Nolet, continue until the Company's 2025 annual meeting of stockholders. The terms of office of the Class III directors, Jill Beraud, Carey O'Connor Kolaja and Dr. Vlad Coric, continue until the Company's 2026 annual meeting of stockholders.
2. The stockholders ratified the selection by the Audit Committee of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024, as follows: 88,457,575 shares of common stock voted for, 849,475 shares of common stock voted against, 82,898 shares of common stock abstaining and no broker non-votes.
3. The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the 2024 Proxy Statement, as follows: 51,554,931 shares of common stock voted for, 18,083,102 shares of common stock voted against, 353,860 shares of common stock abstaining and 19,398,055 broker non-votes.